Lung Cancer
News
FDA approves pembrolizumab for advanced NSCLC
Pembrolizumab had an overall response rate of 41%, and its effect lasted between 2.1 and 9.1 months.
News
FDA approves pembrolizumab for advanced NSCLC
Pembrolizumab had an overall response rate of 41%, and its effect lasted between 2.1 and 9.1 months.
Conference Coverage
ESC: Heart failure patients have increased cancer incidence
Key clinical point: Adults with chronic heart failure had a significantly increased incidence of cancer, compared with the general population....
Video
VIDEO: Think immunotherapy first in relapsed NSCLC
Is it time to think of immunotherapy as a first-line option for relapsed non–small-cell lung cancer?
Conference Coverage
PD-L1 status of NSCLC consistent across primary, nodes, and metastases
Key clinical point: PD-L1 status of the primary in NSCLC generally predicts that of nodal tumor and metastases. Major finding: The rate of...
News
Two trials spotlight atezolizumab activity in advanced lung cancer
Key clinical point: Atezolizumab is clinically active in advanced lung cancer and higher PD-L1 expression correlated with improved response and...
News
Lung adenocarcinoma can harbor both ALK fusions and EGFR driver mutations
Key clinical point: Tumor cells within the same primary tumor were found to harbor both ALK fusions and EGFR driver mutations. Major finding: In...
Conference Coverage
Actionable mutations are highly prevalent in young lung cancer patients
Genomic testing is paramount when lung cancer occurs before age 40.
Conference Coverage
Meta-analysis confirms no OS benefit from antiangiogenics for NSCLC patients
teaser
News
Is Skip N2 metastasis its own category?
teaser